Business, energy, technology, markets and global industry news from Business News Today

Heart Failure Society of America

PharmaDeviceNews Heart Failure Society of America
Editorial infographic showing Bayer’s amyloidosis PET tracer results, with cardiac imaging, a PET scanner and laboratory visuals, highlighting 94% sensitivity in Phase III and new HFSA analyses on earlier diagnosis and finerenone treatment gaps.
Medical Devices & Diagnostics

Bayer’s experimental PET scan detected 94% of cardiac amyloidosis cases. Can it identify the disease earlier?

Bayer's amyloidosis PET tracer showed 94% sensitivity in Phase III. New HFSA analyses examine earlier diagnosis and finerenone treatment gaps.

Read More
Editorial infographic illustrating Affinia Therapeutics’ AFTX-201 BAG3 heart gene therapy programme, featuring an anatomical heart, DNA strands and clinical research imagery, with highlights on the 22-patient trial, promising animal results and unproven human safety and efficacy.
Pharma & Biotech

Affinia presents AFTX-201 preclinical data and UPBEAT trial design at HFSA 2026

Affinia advances AFTX-201 into a 22-patient BAG3 heart gene therapy trial after promising animal results. Human safety and efficacy remain unproven.

Read More
Viz.ai’s HCM data push shows why cardiac AI is shifting from detection to care coordination
Pharma & Biotech

Secretome Therapeutics advances regenerative heart failure research with STM-01 trial data

Secretome Therapeutics reports early STM-01 safety data in 10 HFpEF patients, but unproven efficacy leaves bigger questions for future trials.

Read More